Delving into the Latest Updates on TGRX-1942 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

PTK7

Action

inhibitors

Mechanism

PTK7 inhibitors(Protein-tyrosine kinase 7 inhibitors)

Therapeutic Areas

NeoplasmsHemic and Lymphatic DiseasesRespiratory Diseases

Active Indication

Non-Small Cell Lung CancerRecurrent Hematologic MalignancyAdvanced Malignant Solid Neoplasm

Inactive Indication

Leukemia

Originator Organization

Shenzhen TargetRx, Inc.

Active Organization

Shenzhen TargetRx, Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的（1）剂量递增阶段：评估 TGRX-1942 片治疗晚期实体瘤受试者的安全性、耐受性，探索最大耐受剂量（MTD）以及Ⅱ期推荐剂量（RP2D）。（2）剂量扩展阶段及适应症扩展阶段：按照 RECIST 1.1 标准（和 RANO-BM 标准，2015，如适用）评估 TGRX-1942 片在不同晚期实体瘤中或不同基因突变状态下的有效性。

[Translation]

Main objectives (1) Dose escalation phase: To evaluate the safety and tolerability of TGRX-1942 tablets in the treatment of subjects with advanced solid tumors, and to explore the maximum tolerated dose (MTD) and the recommended dose for phase II (RP2D). (2) Dose expansion phase and indication expansion phase: According to the RECIST 1.1 standard (and RANO-BM standard, 2015, if applicable), evaluate the effectiveness of TGRX-1942 tablets in different advanced solid tumors or different gene mutation states.

Start Date-

Sponsor / Collaborator

Shenzhen TargetRx, Inc.

NCT06484816

/ RecruitingPhase 1

A Dose Escalation and Expansion Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-1942 in Patients with Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies

A phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TGRX-1942 in patients with advanced solid tumor and/or relapsed or refractory hematological malignancies

Start Date08 Jul 2024

Sponsor / Collaborator

Shenzhen TargetRx, Inc.

[+1]

100 Clinical Results associated with TGRX-1942

Login to view more data

100 Translational Medicine associated with TGRX-1942

Login to view more data

100 Patents (Medical) associated with TGRX-1942

Login to view more data

100 Deals associated with TGRX-1942

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Leukemia	Phase 2	China	Shenzhen TargetRx, Inc.	-
Non-Small Cell Lung Cancer	Phase 1	China	Shenzhen TargetRx, Inc.	08 Jul 2024
Recurrent Hematologic Malignancy	Phase 1	China	Shenzhen TargetRx, Inc.	08 Jul 2024
Advanced Malignant Solid Neoplasm	Phase 1	China	Shenzhen TargetRx, Inc.	11 Jun 2024